Summary & Overview
HCPCS J1050: Medroxyprogesterone acetate injection, 1 mg
HCPCS Level II code J1050 denotes an injection of medroxyprogesterone acetate, 1 mg, a commonly used injectable progestin in various clinical settings. Nationally, accurate coding for J1050 affects claims processing, drug utilization tracking, and reimbursement for outpatient injectable therapies. This code is relevant across commercial carriers and public programs due to the routine use of medroxyprogesterone in gynecologic and other hormonal treatment regimens.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service setting, plus what to expect in payer coverage practices. The publication outlines typical billing considerations, benchmarking points, and recent policy updates that influence payment for injectable medications billed with HCPCS codes.
The article provides practical reference material: what J1050 represents clinically, which payers commonly cover the service nationally, and the types of benchmarks and policy content readers can expect. Data not available in the input is clearly noted where applicable.
Billing Code Overview
HCPCS Level II code J1050 describes an injection of medroxyprogesterone acetate, 1 mg. The service type is medication administration (injectable hormonal therapy). The typical site of service is an outpatient clinic or physician office where injectable medications are administered, including specialty clinics that provide hormonal therapies.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a reproductive-age woman seen in an outpatient clinic for contraception management or treatment of dysfunctional uterine bleeding. The clinician prescribes depot medroxyprogesterone acetate (DMPA) injectable progestin and administers J1050 (Injection, medroxyprogesterone acetate, 1 mg) as an intramuscular or subcutaneous injection in the clinic setting. The workflow: patient check-in and medication reconciliation; informed consent and counseling on side effects; confirmation of pregnancy status if clinically indicated; preparation and administration of the injection (usually gluteal or deltoid intramuscular, or subcutaneous for certain formulations); observation for immediate adverse reaction (5–15 minutes); documentation of lot number, dose, route, site, and manufacturer in the medical record; and scheduling of follow-up or next injection. Typical settings include outpatient primary care, family planning clinics, obstetrics-gynecology offices, community health centers, and publicly funded contraceptive clinics. Medicare, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and BUCA payors may cover this service per benefit rules and medical necessity criteria.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed on the same day as and is distinct from the injection encounter (e.g., new problem evaluation plus injection) |